Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 8/20 | 0.41 |
| ▸ | CASP7 | P55210 | 6/20 | 0.41 |
| ▸ | CASP1 | P29466 | 2/20 | 0.41 |
| ▸ | CASP9 | P55211 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10051904 | 0.89 | CASP3 (0.49) | CTSDCASP3CASP7CASP1CASP9 | |
| SCHEMBL11896298 | 0.83 | CASP3 (0.49) | CTSDCASP3 | |
| SCHEMBL2878064 | 0.83 | CASP3 (0.49) | CTSDCASP3 | |
| SCHEMBL20870231 | 0.83 | CASP3 (0.49) | CTSDCASP3 | |
| SCHEMBL11911364 | 0.83 | CASP3 (0.49) | CTSDCASP3 | |
| SCHEMBL11896299 | 0.83 | CASP3 (0.49) | CTSDCASP3 | |
| SCHEMBL11896297 | 0.83 | CASP3 (0.49) | CTSDCASP3 | |
| SCHEMBL2878062 | 0.83 | CASP3 (0.49) | CTSDCASP3 | |
| SCHEMBL23153509 | 0.82 | CASP3 (0.48) | ALDH1A1CTSDCASP3CASP7CASP1 | |
| SCHEMBL3491590 | 0.82 | KDM4C (0.49) | ALDH1A1CASP3CASP7GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173600-B2 | Caspase-2 inhibitors and their biological applications | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-05-08 | — | — | US | disclosed |
| US-20080311051-A1 | Caspase-2 Inhibitors And Their Biological Applications | THERAPTOSIS SA (FR) | 2008-12-18 | — | — | US | disclosed |
| US-20080311051-A1 | Caspase-2 Inhibitors And Their Biological Applications | THERAPTOSIS SA (FR) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311051-A1 | Caspase-2 Inhibitors And Their Biological Applications | CASP1, CASP2, CASP9 | ALDH1A1 2650/4885HPGD 3843/4885CTSD 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.